A Randomized, Double-Blind, Placebo-Controlled, Two-way Crossover Drug-drug Interaction Study to Assess the Effect of Laquinimod 0.6 mg on the Pharmacokinetics and Pharmacodynamics of Ethinylestradiol and Levonorgestrel in Healthy Young Women
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2018
Price : $35 *
At a glance
- Drugs Laquinimod (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Huntington's disease; Multiple sclerosis; Pregnancy
- Focus Pharmacokinetics
- Sponsors Teva Pharmaceutical Industries
- 06 Sep 2018 Results published in the European Journal of Clinical Pharmacology
- 26 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.